Zynex Shares Surge Nearly 30% on Heavy Volume After Q2 Filings

Introduction

Zynex, Inc. (NASDAQ: ZYXI) is a Colorado‐based medical device manufacturer specializing in non-invasive electrotherapy, neurological diagnostics, and cardiac monitoring solutions. Founded in 1996 by CEO Thomas Sandgaard, the company develops and distributes products through three operating units—Zynex Medical, Zynex Monitoring Solutions, and Zynex NeuroDiagnostic—to serve patients with pain, functional disability, and cardiovascular or neurological conditions.

Corporate Structure and Leadership

Zynex maintains a vertically integrated model encompassing research and development, manufacturing, and direct distribution. Its three subsidiaries each focus on a distinct product line:

• Zynex Medical designs home-use TENS, IFC, and NMES devices for pain management and rehabilitation.
• Zynex Monitoring Solutions provides non-invasive cardiac monitors to hospitals and clinics.
• Zynex NeuroDiagnostic offers surface electromyography and autonomic testing equipment.

Thomas Sandgaard, who founded the business with minimal capital, continues as chairman and CEO. The company’s workforce includes personnel in engineering, regulatory affairs, manufacturing, and sales, although Zynex does not disclose total employee count in its public filings.

Electrotherapy by Olga Kononenko

Recent Developments and News

On July 31, 2025, Zynex filed its Form 10-Q for the quarter ended June 30, detailing financial performance and management’s discussion of risk factors, strategic initiatives, and future outlook. On that same date, the company submitted an 8-K report covering material events under Items 2.02 and 9.01, followed by a second 8-K on July 29 (Item 5.02).

On August 4, 2025, shares of ZYXI closed at $1.64, up 29.65% from the previous trading day, on a volume of 2,478,521 shares—well above the 230,193-share average daily turnover.

Financial and Strategic Aspects

According to Yahoo Finance, Zynex reported trailing-twelve-month (TTM) revenue of $144.8 million and a net loss of $28.7 million, yielding a profit margin of –19.8%. The company holds approximately $17.5 million in cash against minimal long-term debt but exhibits a high debt-to-equity ratio. Key valuation and performance metrics include:

• Market capitalization: $38.5 million
• Enterprise value: $93.1 million
• Price/sales (TTM): 0.27
• Price/book (MRQ): 30.3
• Beta (5-year monthly): 0.92

Gross margins are reported at around 80%, reflecting the device-oriented revenue mix. An independent research consensus assigns a Hold rating with a $6.00 target price, noting medium growth prospects offset by low financial strength and management subratings.

Market Position and Industry Context

Zynex operates within the broader medical device industry, competing in electrotherapy and non-invasive monitoring segments. The company benefits from rising demand for alternatives to opioid pain treatments and remote patient monitoring. Regulatory approvals, including FDA clearance in February 2020 for its CM-1500 Cardiac Monitor, are noted as important for market diversification. Zynex also faces challenges from reimbursement policy shifts and competition from established device manufacturers.

tl;dr

On August 4, 2025, Zynex shares rose 29.65% to $1.64 on high trading volume. The company’s Q2 2025 10-Q and two 8-K filings on July 29 and July 31 provided updated financials and strategic commentary. With TTM revenue near $145 million, a net loss of $28.7 million, and an 80% gross margin, Zynex trades at a 0.27 price/sales ratio. Analyst consensus is Hold with a $6.00 target.